<DOC>
	<DOCNO>NCT00986895</DOCNO>
	<brief_summary>The purpose study determine safety tolerability GT4P administer orally single dose , twice daily 7 consecutive day , subject hepatic impairment cirrhosis ( Child-Pugh score A , B , C ) gender match similar age control group normal hepatic function .</brief_summary>
	<brief_title>A Study Glyceryl Tri- ( 4-phenylbutyrate ) Administered Orally Single Dose , Twice Daily Seven Consecutive Days Subjects With Hepatic Impairment With Cirrhosis Control Group</brief_title>
	<detailed_description />
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<mesh_term>Urea Cycle Disorders , Inborn</mesh_term>
	<mesh_term>4-phenylbutyric acid</mesh_term>
	<criteria>Subjects require fulfill follow criterion order participate study : Screening : Males female age ≥ 18 year age Able provide write informed consent studyrelated procedure , ability , opinion Investigator , comply requirement study Classification one following : current diagnosis hepatic impairment cirrhosis healthy subject Subjects hepatic impairment cirrhosis classifiable one follow group : ChildPugh score A ChildPugh score B ChildPugh score C Subjects hepatic impairment cirrhosis therapeutic regimen lactulose must stable dose ≥ 30 day prior screen If female , negative pregnancy test screen predose day 0 , document sterilization procedure ; female childbearing potential must use medically approve birth control method must agree use method contraception full course study ( predose day 0 well screen ) Weight within range 60100 kg ( screen predose day 0 ) Willing stop take medication Sponsor Investigator felt appropriate use study , begin 2 day dose throughout study Subjects fulfil follow criterion exclude study : Screening : Clinically significant history evidence cardiovascular , respiratory , renal , gastrointestinal , endocrine , neurological , immunological , psychiatric disorder ( ) , determine Investigator Serum sodium &lt; 120 mEq/L Serum creatinine ≥ 1.5 upper limit normal Potassium ≤ 3.5 mEq/L Other laboratory value outside normal range determine clinically significant Investigator Significant illness within last 14 day Oral temperature &gt; 38.5°C &lt; 36°C and/or suspect site active infection Inflammatory bowel disease malabsorption define steatorrhea Active gastrointestinal bleeding , define melena , hematochezia , hematemesis require hospitalization within last 30 day Use probenecid , valproate , corticosteroid within last 24 hour Use medication , approve Sponsor Investigator , last 48 hour History seizure within last 72 hour Positive drug abuse urine test Positive alcohol breath test Donation loss blood ( 500 mL ) within last 30 day Donation loss plasma within last 7 day History acquire immunodeficiency syndrome ( AIDS ) determine human immunodeficiency virus ( HIV ) positive Hepatitis B C ( HBV ; HCV ) positive ( healthy volunteer ) Use investigational drug within last 30 day Known hypersensitivity sodium phenylbutyrate similar drug Emergency hospitalization within last 90 day Intake alcohol last 7 day Predose ( day 0 7 ) : Significant illness emergency hospitalization since last study visit Oral temperature &gt; 38.5°C &lt; 36°C and/or suspect site active infection Use probenecid , valproate , corticosteroid within last 24 hour Use nonapproved medication ( Sponsor/Investigator ) within 48 hour dose History seizure within last 72 hour Positive drug abuse urine test Positive alcohol breath test Donation loss blood ( 500 mL ) plasma since last study visit Use investigational drug since last study visit Intake alcohol last 7 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>HPN-100</keyword>
	<keyword>GT4P</keyword>
	<keyword>Glyceryl tri- ( 4-phenylbutyrate )</keyword>
</DOC>